{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for telotristat root_Display\ Name in Display Name (approximate match)
Status:
Investigational
Source:
JAN:L-TYROSINE ETHYLESTER MONOHYDROCHLORIDE [JAN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Tyrosine ethyl ester hydrochloride is used as a medical and organic intermediate and as an important amino protective agent. It is also used to introduce t-Boc protect gene. Tyrosine ethyl ester hydrochloride is used as a supplement (tyrosine).
Status:
Investigational
Source:
NCT01693159: Not Applicable Interventional Unknown status Pain
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT01121614: Not Applicable Interventional Completed Surgery
(2008)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Cinidon-ethyl (BAS 615H) is a herbicide of isoindoldione class which selectively controls a wide spectrum of broadleaf weeds in cereals. Cinidon‐ethyl strongly inhibited protoporphyrinogen oxidase (Protox) activity in vitro, with I50 values of approximately 1 nM for the enzyme isolated from the weed species and from wheat. Cinidon-ethyl was approved in the EU in the early 2010s, but authorization was revoked due to lack of interest from the applicant.
Status:
Investigational
Source:
NCT03184545: Phase 3 Interventional Recruiting Patellofemoral Pain Syndrome
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
Cancer. Aug 1993;72(4):1184-91.: Phase 2 Human clinical trial Completed Neoplasm Recurrence, Local/mortality
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
Gastroenterology. Jan 2009;136(1):56-64; quiz 351-2.: Phase 3 Human clinical trial Completed Barrett Esophagus/pathology
Source URL:
Class (Stereo):
CHEMICAL (UNKNOWN)
Status:
Class (Stereo):
CHEMICAL (RACEMIC)
Ethyl dirazepate is an anticonvulsant compound.
Status:
Investigational
Source:
INN:caloxetic acid [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Caloxetate Trisodium is triazaundecanedioic acid derivative patented by German pharmaceutical company as liver-specific magnetic resonance imaging contrast agent.
Status:
Investigational
Source:
NCT00004049: Phase 1 Interventional Completed Unspecified Adult Solid Tumor, Protocol Specific
(1999)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Tetraisopropyl 2-(3,5-Di-Tert-Butyl-4-Hydroxyphenyl)Ethyl-1,1-Biphosphonate (also known as SR-9223I and SR 45023A) is a gem-diphosphonate derivative patented by Symphar S. A. as an antihypertensive and anti-inflammatory agent. Tetraisopropyl 2-(3,5-Di-Tert-Butyl-4-Hydroxyphenyl)Ethyl-1,1-Biphosphonate acts as 3-hydroxy-3-methylglutaryl reductase inhibitor, besides that SR-9223I suppresses acyl-CoA: cholesterol acyltransferase activity and prevents the oxidation of plasma lipoproteins. In preclinical studies, SR-9223i reduces blood cholesterol concentrations in mice, hamsters, dogs, and monkeys. SR-9223i inhibits the growth of a wide variety of tumor cell lines in vitro and triggered apoptosis in HL60 cells in less than 2 h. SR-9223i induces caspase-3 activity at concentrations similar to it’s IC(50) values for cell proliferation. Unfortunately, in clinical trials SR-9223I failed to demonstrate efficacy in patients with refractory melanoma and further development was discontinued.
Status:
Investigational
Source:
INN:tenifatecan [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Tenifatecan (also known as SN2310 or tocopherol succinate-SN38), camptothecin, is an injectable emulsion composed of vitamin E, a succinate derivative, as well as 7-ethyl-10-hydroxycamptothecin (SN-38), the active metabolite of irinotecan. It is known that SN-38 binds to and inhibits topoisomerase I by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks, inhibition of DNA replication, and apoptosis. Tenifatecan successfully completed phase I clinical trial in patients with advanced solid tumors. Achieve Life Sciences, the company that is developing this drug, are currently exploring options to out-license tenifatecan.
